Targeting Aurora A kinase (AURKA) and p21-activated kinase 1 (PAK1) in hormone receptor-positive breast cancer by Feng, Yayi
 
 
 
 
 
 
TARGETING AURORA A KINASE (AURKA) AND P21-ACTIVATED KINASE 1 
(PAK1) IN HORMONE RECEPTOR-POSITIVE BREAST CANCER 
 
By 
Yayi Feng 
 
November 2016 
 
A Dissertation Presented to the Faculty of 
Drexel University College of Medicine 
in partial fulfillment of the Requirements for the Degree of 
Master of Science in Cancer Biology 
 
 
 
_____________________________  _____________________________ 
  Erica Golemis, PhD (Mentor)      Mauricio Reginato, PhD (Chair) 
Adjunct Professor         Professor 
Biochemistry & Molecular Biology   Biochemistry & Molecular Biology 
Drexel University College of Medicine  Drexel University College of Medicine 
 
 
 
_____________________________ 
Jonathan Chernoff, MD, PhD 
Adjunct Professor 
Biochemistry & Molecular Biology 
Drexel University College of Medicine
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Yayi Feng 
2016
ii 
 
TABLE OF CONTENTS 
 
LIST OF TABLES ...................................................................................................... 
 
iii 
LIST OF FIGURES ..................................................................................................... 
 
iv 
ABSTRACT ................................................................................................................ 
 
v 
INTRODUCTION ....................................................................................................... 
 
1 
MATERIALS AND METHODS ................................................................................ 
 
15 
Cell lines and cell culture......................................................................................... 
 
15 
Reagents .................................................................................................................. 
 
15 
Cell Viability Assay ................................................................................................ 
 
18 
Breast cancer mouse model and tissue collection ................................................... 
 
18 
Preparation of Tumor Lysates ................................................................................. 
 
20 
Western Blotting ..................................................................................................... 
 
20 
Immunoprecipitation and in vitro Kinase Assay ..................................................... 
 
21 
Statistical Analysis .................................................................................................. 
 
23 
RESULTS .................................................................................................................... 
 
23 
Inhibition of AURKA and PAK1 synergistically hampers cell survival of breast 
cancer cells in vitro and limits growth of mammary tumor xenografts in vivo ...... 
 
 
23 
Combination of alisertib and FRAX1036 suppresses proliferation and promotes 
apoptosis in vivo ...................................................................................................... 
 
 
27 
Combined treatment with alisertib and FRAX1036 reduces estrogen receptor α 
(ERα) phosphorylation and signaling activity in HR-positive breast cancer .......... 
 
 
31 
DISCUSSION ............................................................................................................. 
 
36 
LIST OF REFERENCES ............................................................................................ 44 
iii 
 
LISTS OF TABLES 
 
Table 1. List of Antibody Information ........................................................................ 
 
17 
Table 2. Molecular Phenotypes of BT474 and T47D ................................................. 23 
  
iv 
 
LISTS OF FIGURES 
 
Figure 1. Structure of estrogen receptor α (ERα) ........................................................... 
 
2 
Figure 2. ERα, AURKA, and PAK1 signaling network ................................................. 
 
14 
Figure 3. Dual inhibition of AURKA and PAK1 by alisertib and FRAX1036 impairs 
survival of breast cancer cells in vitro and limits breast tumor growth in vivo ................ 
 
 
25 
Figure 4. Combination of alisertib and FRAX1036 suppresses proliferation and 
promotes apoptosis in vivo ........................................................................................... 
 
 
29 
Figure 5. Concurrent use of alisertib and FRAX1036 decreases phosphorylation of 
PAK1 and AURKA kinase activity in tamoxifen-resistant breast cancer ....................... 
 
 
34 
Figure 6. Combined treatment with alisertib and FRAX1036 reduces ERα 
phosphorylation and signaling activity in tamoxifen-resistant breast cancer .................. 
 
 
35 
  
v 
 
ABSTRACT 
Targeting Aurora A Kinase (AURKA) and p21-activated kinase 1 (PAK1) in 
hormone receptor-positive breast cancer 
Yayi Feng 
Advisor: Erica Golemis 
 
Estrogen receptor α (ERα) is a hormone-dependent nuclear and cytoplasmic receptor that 
regulates many physiological processes, such as reproduction, bone integrity, 
cardiovascular health, cognition, and behavior. Activation of the ERα pathway plays a 
crucial role in the development and progression of breast cancer, with 70-80% of breast 
tumors being positive for hormonal receptors and driven by ERα signaling. Drugs 
targeting estrogen receptor, such as tamoxifen and fulvestrant, are used in the clinic to 
treat ERα positive metastatic breast cancer. However, resistance to these therapies 
ultimately develops and represents a very significant clinical problem.  
 
One of the mechanisms of endocrine resistance is ligand-independent activation of ERα 
by intracellular protein kinases. Mitotic kinase Aurora A kinase (AURKA) activates ERα 
through phosphorylation at serine 167 and serine 305. P21-activated kinase 1 (PAK1), a 
kinase known as a key regulator of MAPK pathway and cytoskeleton remodeling, also 
modulates ERα activation through phosphorylating serine 118 and serine 305. 
Phosphorylation at these serine residues has been correlated with the increased ERα 
signaling and clinical outcomes.  
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Herein, we show that pharmacological inhibition of AURKA and PAK1 synergistically 
decreases cell survival of both tamoxifen-resistant and tamoxifen-sensitive breast cancer 
cell lines in vitro. Further, in vivo study demonstrates that dual inhibition of AURKA and 
PAK1 limits growth of breast tumors and leads to increased apoptosis, especially in 
tamoxifen-resistant xenograft tumors. In vitro experiments show differentiated signaling 
patterns in tamoxifen-resistant and tamoxifen-sensitive breast cancer upon combination 
treatment. Taken together, these data suggest that targeting AURKA and PAK1 may be a 
promising therapeutic strategy for hormone receptor-positive breast cancer, especially in 
the settings of endocrine resistance. 
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INTRODUCTION 
 
Breast cancer is the most commonly diagnosed malignancy among women in both 
developing and developed regions (Ferlay, Soerjomataram et al. 2015). In the United 
States, it is estimated that about 246,660 women will be diagnosed with breast cancer in 
2016 (Howlader, Noone et al. 2016). Although the death rate in the U.S. decreased by 1.9% 
per year from 2003 to 2012, breast cancer is still the second leading cause of cancer-
related death among women after lung cancer, and it is estimated that there will be 
40,450 new cases of death from breast cancer in 2016 (Howlader, Noone et al. 2016, 
Ryerson, Eheman et al. 2016).  
 
Breast cancer is classified according to the expression of the estrogen receptor (ER), the 
progesterone receptor (PR), and human epidermal growth factor receptor 2 
(HER2/ERBB2/neu) as assessed by immunohistochemistry and in situ hybridization in 
tumor samples (Hammond, Hayes et al. 2010, Wolff, Hammond et al. 2014). Therefore, 
breast cancer can be categorized as one of three main subtypes: hormone receptor (HR)-
positive (ER or/and PR-positive), HER2/neu-positive, and triple negative (ER, PR and 
HER2/neu-negative). The status of these receptors is prognostic and widely used to 
forecast patients’ clinical outcomes. Since ER and HER2 are well-known therapeutic 
targets, these biomarkers also determine treatment options. 
 
The HR-positive subtype accounts for approximately 80% of all breast cancer cases 
(Howlader, Altekruse et al. 2014, Wu, Cheng et al. 2016). Anti-hormonal therapy, also 
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known as endocrine therapy, suppresses HR signaling either by decreasing production of 
ER ligands, or by inhibiting ER activity. Tamoxifen, a selective ER modulator, is one of 
the endocrine agents widely used in clinics for decades. However, some patients do not 
respond to tamoxifen (de novo resistance), and a large proportion of individuals who 
initially benefit from tamoxifen treatment, develop resistance over time (acquired 
resistance) (Ring and Dowsett 2004). Several mechanisms underlying de novo and 
acquired endocrine resistance have been proposed based on dysfunction of ERα signaling, 
including mutations of ESR1 (ERα-coding gene), loss of ER expression, and ligand-
independent activation of ERα by intracellular protein kinases(Lapidus, Nass et al. 1998, 
Robinson, Wu et al. 2013, Nardone, De Angelis et al. 2015).  
 
 
 
ERs are found mainly in nucleus and cytoplasm, although a small fraction of ERs may be 
localized near or at the plasma membrane (Arpino, Wiechmann et al. 2008). There are 
two types of ER, ERα and ERβ, encoded by two different genes, ESR1 and ESR2, 
respectively (Menasce, White et al. 1993, Enmark, Pelto-Huikko et al. 1997). Both ER 
subtypes consist of four functional domains (Fig.1): a ligand-independent activation 
function-1 (AF-1) domain next to the N-terminus, a DNA binding domain (DBD), a 
 
 
Figure 1. Structure of estrogen receptor α (ERα).  AF – activation function domain, 
DBD – DNA binding domain, H – hinge domain, LBD – ligand binding domain. 
(Modified from(Shagisultanova, Korobeynikov et al. 2016) 
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hinge domain (H), and an activation function-2 (AF-2) domain/ligand-binding domain 
adjacent to the C-terminus (Deroo and Korach 2006). ERα and ERβ are expressed in 
various tissues including mammary gland, and play important roles in several 
physiological processes, such as reproduction, cardiovascular health, bone integrity, 
cognition, and behavior (Enmark, Pelto-Huikko et al. 1997, Deroo and Korach 2006). 
Both ERα and ERβs are co-expressed in normal breast epithelial cells, and ERβ 
expression is predominant in normal human mammary gland (Enmark, Pelto-Huikko et al. 
1997, Huang, Omoto et al. 2014). Expression of ERα is significantly increased in ductal 
carcinoma in situ (DCIS), whereas ERβ expression is less abundant in breast cancer, and 
is lost in most of invasive ductal carcinoma (IDC) samples (Huang, Omoto et al. 2014). 
Therefore, ERα plays an important role in promoting breast malignancies, whereas ERβ 
might function as tumor suppressor (Osborne, Schiff et al. 2001). 
 
As a pivotal regulator involved in the development and progression of breast cancer, ERα 
can exert genomic effects as a ligand-dependent transcription factor that modulates 
transcription of genes involved in cell cycle regulation, apoptosis, and tumor progression. 
In genomic signaling, ERα ligands such as 17β-estradiol (E2) diffuse into cells and bind 
to nuclear ERα at the ligand-binding domain, which induces conformational change and 
dimerization of ERα (Osborne, Schiff et al. 2001, Arpino, Wiechmann et al. 2008). The 
ER dimer translocates to palindromic estrogen response elements (EREs) in promoter 
region or 3’-flanking region of target genes (Carroll, Meyer et al. 2006, Kwon, Garcia-
Bassets et al. 2007). This leads to recruitment of co-activator or co-repressor proteins that 
enhance or suppress transcription of the ER-targeted genes, such as VEGF and PS2 
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(Stack, Kumar et al. 1988, Applanat, Buteau-Lozano et al. 2008). The activated ERα 
dimer also modulates transcription of E2-responsive genes through direct protein-protein 
interaction with other transcription factors including Sp1, AP1, and NF-κB (Porter, Wang 
et al. 1996, Paech, Webb et al. 1997, Glidewell-Kenney, Weiss et al. 2005). Transcription 
of several oncogenic genes such as c-Myc, CCND1, and Bcl-2 are regulated through this 
“tethering mechanism” (Dong, Wang et al. 1999, Glidewell-Kenney, Weiss et al. 2005, 
Wang, Mayer et al. 2011). Promoters of ER-targeted genes are usually activated 
synergistically by AF-1 and AF-2 domains of ERα. The AF-1 domain is constitutively 
active or exerts transactivation effect in a ligand-independent manner, whereas 
transcriptional activity of AF-2 domain relies on ligand binding (Arpino, Wiechmann et 
al. 2008).  
 
Beside the genomic effect, ERα also rapidly (in minutes) influences several signaling 
pathways independent of its function as a transcription factor (Arpino, Wiechmann et al. 
2008). These non-genomic effects, at least in part, are induced by extra-nuclear full-
length ERα or its variants (Li, Haynes et al. 2003, Wang, Zhang et al. 2006). In the non-
genomic pathway, ligand-bound ERα binds to membrane proteins such as caveolin-1 and 
flotillin-2, tethered on the inner face of plasma membrane (Marquez, Chen et al. 2006, 
Pedram, Razandi et al. 2007). Membrane-bound ERα interacts directly and forms large 
complexes with other membrane receptors including HER2, IGF-1R, and EGFR 
(Márquez, Lee et al. 2001, Song, Barnes et al. 2004, Marquez, Chen et al. 2006). Several 
downstream signaling molecules and functional domains such as c-Src (Razandi, Pedram 
et al. 2000), Shc (Song, Barnes et al. 2004), distinct G protein subunits (Wyckoff, 
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Chambliss et al. 2001, Razandi, Pedram et al. 2003), and NMAR (Barletta, Wong et al. 
2004) interact with ERα. The formation of a large “signalosome” complex results in bi-
directional crosstalk between ERα and other receptors, as well as subsequent rapid signal 
transduction through routes like PI3K/AKT and RAS/RAF/MEK/ERK pathways (Arpino, 
Wiechmann et al. 2008).  
 
ERα dimerization, localization and function are regulated through post-translational 
modification. ERα can be phosphorylated on serine and tyrosine residues by intracellular 
protein kinases including AKT, PKA, MAPK, P21-activated protein 1 (PAK1), and 
Aurora A kinase (AURKA) (Joel, Smith et al. 1998, Chen, Pace et al. 1999, Campbell, 
Bhat-Nakshatri et al. 2001, Wang, Mazumdar et al. 2002, Michalides, Griekspoor et al. 
2004, Rayala, Talukder et al. 2006, Thomas, Sarwar et al. 2008, Zheng, Guo et al. 2014). 
Multiple ERα phosphorylation sites (S104/106, S118, S167, S282, S294, S305, T311, 
and S559) have been identified, and phosphorylation at some of these sites is correlated 
with clinical outcomes (Skliris, Nugent et al. 2010, Murphy, Seekallu et al. 2011). 
Intracellular protein kinases AURKA and PAK1 phosphorylate ERα at S167 and S118, 
respectively, and both phosphorylate S305 (Wang, Mazumdar et al. 2002, Rayala, 
Talukder et al. 2006, Zheng, Guo et al. 2014). Expression of AURKA (Zheng, Guo et al. 
2014) and PAK1 (Holm, Rayala et al. 2006, Kok, Zwart et al. 2011) are associated with 
tamoxifen resistance, leading to the hypothesis that these activities may involve control 
of ERα activity. 
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AURKA is a serine/threonine protein kinase that belongs to the Aurora/IPL1-related 
kinase family. It is a key regulator of mitosis that controls all aspects of cell division 
including centrosome maturation and separation, assembly and control of a bipolar 
spindle, timing of mitotic entry, chromosome alignment in the metaphase, and 
cytokinesis(Nikonova, Astsaturov et al. 2013). Beside its crucial role in maintaining 
mitosis and genetic integrity, AURKA influences other cellular processes such as 
microtubule dynamics, cell motility, cell polarity, ciliary disassembly, and calcium 
regulation (Nikonova, Astsaturov et al. 2013). 
 
AURKA consists of three domains: an N-terminal regulatory domain, a highly conserved 
catalytic kinase domain, and a short C-terminal domain. Crystallography showed that the 
catalytic domain contains two lobes (N-lobe and C-lobe), which form a bi-lobal 
architecture commonly seen in other protein kinases (Nowakowski, Cronin et al. 2002). 
An activation loop of AURKA in the C-lobe contains a key threonine residue T288, 
phosphorylation of which is required for AURKA activation. Two regulatory sequences – 
a D-box in the C-terminus of the catalytic domain, and an A-box within the N-terminal 
domain – serve as recognition sites for AURKA degradation at the last stage of mitosis 
(Marumoto, Zhang et al. 2005).  
 
Gene expression, activation and degradation of AURKA during cell cycle are tightly 
regulated both spatially and temporally. During S phase, AURKA begins to gather 
around the centrosomes, and a small fraction of AURKA becomes activated before 
chromosome condensation in G2 phase (Marumoto, Zhang et al. 2005). AURKA 
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continues to accumulate, and level of activated AURKA increases dramatically after the 
cells enter prophase (Carmena and Earnshaw 2003). A small proportion of activated 
AURKA moves to nucleus during the chromosome condensation (Marumoto, Zhang et al. 
2005). After the breakdown of nuclear envelope, activated AURKA in spindle poles 
starts to spread along the mitotic spindles to mid-zone during the transition from 
metaphase to anaphase (Marumoto, Zhang et al. 2005, Nikonova, Astsaturov et al. 2013). 
Most of AURKA is inactivated during the transition, and only a small amount of 
AURKA are found at the mid-zone and centrosome during telophase (Marumoto, Zhang 
et al. 2005). AURKA is mostly degraded before the cytokinesis, and protein level of 
AURKA is low and undetectable when the cells enter G1 phase (Marumoto, Zhang et al. 
2005, Nikonova, Astsaturov et al. 2013). 
 
Proper function of AURKA in cell cycle requires precise cooperation with a variety of 
other protein partners. AURKA activating partners such as Bora, NEDD9, and TPX2 
induce AURKA auto-phosphorylation at T288 within activation loop (Nikonova, 
Astsaturov et al. 2013). AURKA works with Bora to promote activation of CDK1/cyclin 
B complex through PLK1 phosphorylation, which allows mitotic entry (Seki, Coppinger 
et al. 2008). Bora and NEDD9 – a scaffold protein involved in focal adhesion – facilitate 
AURKA-induced centrosome maturation (Pugacheva and Golemis 2005, Hutterer, 
Berdnik et al. 2006). Another AURKA activating protein, TPX2, is released from 
importin-α/β inhibitory complex by Ran-GTP during the breakdown of nuclear envelope 
(Tsai, Wiese et al. 2003). Free TPX2 interacts with AURKA and releases it from 
inhibition by phosphatase P2A (PP2A). It helps AURKA localization on spindle 
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microtubules, and assists in its interaction with other substrates (Kufer, Sillje et al. 2002, 
Carmena and Earnshaw 2003, Eyers, Erikson et al. 2003). AURKA destruction is 
required for cytokinesis and mitotic exit. Proteasomal degradation of AURKA is 
mediated by the anaphase-promoting complex/cyclosome (APC/C) and Cdh1 (Taguchi, 
Honda et al. 2002). The A-box and D-box of AURKA are required for AURKA 
ubiquitination during Cdh1-dependent proteolysis (Littlepage and Ruderman 2002). The 
E3 ubiquitin ligase Chfr can directly ubiquitinate A-box for AURKA degradation (Yu, 
Minter-Dykhouse et al. 2005). PP2A modifies A-box through dephosphorylation of S51, 
which disrupts AURKA stability and promotes AURKA turnover (Horn, Thelu et al. 
2007). Proteasomal degradation of AURKA can be regulated by Aurora A kinase 
interacting protein 1 (AIP) by promoting interaction of AURKA and Az1, a well-studied 
mediator of ubiquitination-independent protein degradation pathway (Lim and Gopalan 
2007).  
 
High levels of AURKA mRNA and protein expression have been identified in various 
cancer cell lines and solid tumors including breast carcinoma. AURKA is amplified in 
approximately 12% of primary breast tumors and breast cancer cell lines and is 
overexpressed in about 80-90% of breast tumors (Zhou, Kuang et al. 1998). The 
phenotype of AURKA overexpression includes aneuploidy, supernumerary centrosomes 
associated with multipolar spindles, increased resistance to apoptosis, and deficient cell 
cycle checkpoint functions (Nikonova, Astsaturov et al. 2013). AURKA overexpression 
has a strong correlation with worse survival (Nadler, Camp et al. 2008), especially in 
patient with ERα positive tumors (Zheng, Guo et al. 2014). Gene expression of AURKA 
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in ER-positive breast cancer is regulated by ERα through activation of transcription 
factor GATA-3 (Jiang, Katayama et al. 2010). Additionally, AURKA enhances ERα 
activity through direct ligand-independent phosphorylation of S167 and S305 (Zheng, 
Guo et al. 2014). Notably, ERα phosphorylation at S305 is involved in endocrine 
resistance and enhanced transcription of oncogene CCND1, which is commonly 
upregulated in breast cancer (Balasenthil, Barnes et al. 2004). Further, AURKA 
overexpression caused by constitutively active RAF1 induces epithelial- mesenchymal 
transition (EMT) in ERα-positive breast cancer cells (D'Assoro, Liu et al. 2014) 
correlating with tumor progression, metastasis, and resistance to standard therapy 
(Creighton, Li et al. 2009, Giancotti 2013, Piva, Domenici et al. 2014).  
 
Alisertib (MLN8237), a selective AURKA inhibitor, has been tested in preclinical and 
clinical studies (Cervantes, Elez et al. 2012, Melichar, Adenis et al. 2015). In preclinical 
experiments, ectopic expression of AURKA induced tamoxifen resistance, while 
AURKA depletion and pharmacological inhibition by alisertib sensitized tamoxifen-
resistant cells to tamoxifen treatment (Zheng, Guo et al. 2014). Alisertib reverses EMT 
and suppresses self-renewal ability, and thus inhibits breast cancer metastasis (D'Assoro, 
Liu et al. 2014). A phase II clinical study demonstrated that alisertib as a single agent had 
a promising therapeutic effect in heavily pretreated patients, especially those with HR-
positive breast cancer (Melichar, Adenis et al. 2015).  
 
In summary, preclinical and clinical studies demonstrated the signaling interplay between 
AURKA and ERα, implicated AURKA activation in tumorigenesis of HR-positive breast 
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cancer, and identified AURKA as a potential therapeutic target in HR-positive breast 
cancer. 
 
Similar to AURKA, PAK1 is a serine/threonine intracellular protein kinase. It is a 
member of p21-activated kinase family. PAK1 is a well-known effector for the small 
GTPases Cdc42 and Rac. It is involved in upregulation of the MAPK pathway, 
cytoskeleton rearrangement, cell polarity, motility, and invasion. PAK1 functions as a 
critical rheostat that integrates and orchestrates several signaling pathways and thus 
influences cellular processes including proliferation, angiogenesis, stress response, 
mitogenesis, and apoptosis (Arias-Romero and Chernoff 2008, Wertheimer, Gutierrez-
Uzquiza et al. 2012, Radu, Semenova et al. 2014).  
 
PAK1 has an N-terminal regulatory domain and a conserved C-terminal catalytic domain. 
Within the N-terminal domain, a conserved P21-GTPase binding domain (GBD) overlaps 
with autoinhibitory domain (AID). GBD is the binding region for active form of Cdc42 
or Rac GTPases (Radu, Semenova et al. 2014). Two SH3-binding motifs and a non-
classical SH3 binding site are also identified within the regulatory domain. Two SH3-
binding motifs are binding sites for adaptor proteins NEK and GRB2, respectively, which 
indicates that PAK1 can be recruited to plasma membrane. The non-classical binding site 
is responsible for interaction with the guanine-nucleotide-exchange factor PIX and PAK1 
translocation to focal adhesion (Arias-Romero and Chernoff 2008). PAK1 has an 
activation loop within the catalytic domain, and phosphorylation at T423 within the loop 
is crucial for catalytic function (Gatti, Huang et al. 1999). 
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PAK1 activation is regulated in trans-autoinhibition manner (Lei, Lu et al. 2000). When 
PAK1 is in the inactive state, two PAK1 molecules form a homodimer, in which the AID 
of one PAK1 molecule attaches to the catalytic domain of its partner (Radu, Semenova et 
al. 2014).  Cdc42 and Rac get activated by various stimuli (e.g., stress, integrin, receptor 
tyrosine kinases, and G-protein coupled receptors), and bind to the GBD of PAK1 
(Wertheimer, Gutierrez-Uzquiza et al. 2012). This interaction and coincident binding of 
phosphoinositide leads to the release of the AID from the catalytic domain of its partner, 
conformational change of PAK1, and autophosphorylation of PAK1 (Pirruccello, 
Sondermann et al. 2006, Arias-Romero and Chernoff 2008). PAK1 further 
autophosphorylates at multiple sites, including S144, S199, and S204, which enables 
PAK1 to maintain a catalytically active state (Gatti, Huang et al. 1999). PAK1 activity 
can be modulated through phosphorylation by other cellular protein kinases such as AKT 
(Zhou, Zhuo et al. 2003), binding with NEK or GRB2 at SH3-binding motifs, and 
binding with PIX at PIX-binding site (Radu, Semenova et al. 2014). 
 
PAK1 regulates cytoskeleton rearrangement through phosphorylation of downstream 
targets such as LIM kinase (LIMK), Myosin light chain kinase (MLCK), and Arpc1b 
(Edwards, Sanders et al. 1999, Sanders, Matsumura et al. 1999, Vadlamudi, Li et al. 
2004). PAK1 phosphorylation and activation of LIMK leads to subsequent 
phosphorylation of the LIMK substrate Cofilin, which suppresses Cofilin activity to 
depolymerize actin filaments and thus induces actin-filament stabilization (Yang, Higuchi 
et al. 1998). MLCK regulates interaction of actin and myosin II by phosphorylation and 
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activation of the regulatory myosin light chain (MLC). PAK1 impairs MLC activity by 
phosphorylation and inhibition of MLCK and thus induces acto-myosin contraction 
(Sanders, Matsumura et al. 1999). PAK1 controls cell motility through Arpc1b, a subunit 
of Arp2/3 complex. Arpc1b phosphorylation by PAK1 promotes its localization with 
Arp2/3 complex, which drives formation of branched actin filament networks and 
extension of the cell's leading edge (Vadlamudi, Li et al. 2004). Beside its functions in 
cell morphology, PAK1 prevents apoptosis through RAF and pro-apoptotic protein BAD. 
Upon phosphorylation by PAK1, RAF translocates to mitochondria and phosphorylates 
Bad (Tran and Frost 2003). PAK1 also can phosphorylate Bad directly (Schurmann, 
Mooney et al. 2000). This impairs binding of Bad and Bcl-2, and thus promotes cell 
survival. Additionally, PAK1 is involved in cell cycle progression. PAK1 is 
phosphorylated by cyclin B1/Cdc2 complex during mitosis and localizes to chromatin. 
Activated PAK1 modifies histone H3 through phosphorylation, which is essential for the 
initiation of chromosome condensation and cell cycle progression (Li, Adam et al. 2002). 
Interestingly, PAK1 activates AURKA through direct phosphorylation of T288 in mitotic 
cells (Zhao, Lim et al. 2005). PAK1 also facilitates AURKA function by phosphorylating 
AURKA activating partners LIMK and Arpc1b, as well as AURKA substrate PLK1 
(Edwards, Sanders et al. 1999, Vadlamudi, Li et al. 2004, Maroto, Ye et al. 2008). 
Moreover, PAK1 also promotes cell proliferation through activation of RAF/MEK/ERK 
signaling and β-catenin translocation to nucleus, which stimulates expression of Cyclin 
D1 (encoded by CCND1) driving cell cycle progression (Balasenthil, Sahin et al. 2004, 
Radu, Semenova et al. 2014). In addition to migration, cytoskeleton reorganization, 
proliferation, and apoptosis, PAK1 regulates angiogenesis (Radu, Semenova et al. 2014).  
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Hyperactivation and high expression of PAK1 is found in a variety of cancers, including 
brain, breast, liver, kidney, colon, lung, and ovarian tumors (Ye and Field 2012). 
Transgenic mice with PAK1 overexpression develop invasive breast cancer (Wang, 
Zhang et al. 2006). One of the mechanisms underlying dysfunction of PAK1 is gene 
amplification. PAK1 gene is located in the chromosomal region 11q13, in which other 
oncogenes such as CCND1 are clustered (Schraml, Schwerdtfeger et al. 2003). 
Amplification of this region is found in various types of cancer and correlates with poor 
prognosis in breast cancer. It should be noted, however, that overexpression of PAK1 
does not always coexist with PAK1 gene amplification (Radu, Semenova et al. 2014). 
Studies have shown that high PAK1 expression is associated with decreased tamoxifen 
sensitivity in pre-menopausal breast cancer patients (Holm, Rayala et al. 2006, Rayala, 
Talukder et al. 2006, Bostner, Ahnstrom Waltersson et al. 2007). Similar to AURKA, 
PAK1 can phosphorylate ERα at serine 305, followed by phosphorylation at serine 118, 
which suggests that ligand-independent activation of ERα by PAK1 may lead to 
endocrine resistance. A preclinical study supported this idea by inhibiting PAK1 activity 
using a histone deacetylase (HDAC) inhibitor FK228, showing that FK228 suppresses 
estrogen-dependent growth of both tamoxifen-resistant and tamoxifen-sensitive human 
breast cancer (Hirokawa, Arnold et al. 2005).  
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Figure 2. ERα, AURKA, and PAK1 signaling network. E2 - 17β-estradiol 
(Modified from(Shagisultanova, Korobeynikov et al. 2016) 
 
Taken together, these studies suggest a signaling network between ERα, AURKA, and 
PAK1 (Fig. 2). In this model, PAK1 activates AURKA and its activating partners LIMK 
and Arpc1b through direct phosphorylation (Edwards, Sanders et al. 1999, Vadlamudi, Li 
et al. 2004, Zhao, Lim et al. 2005). PAK1 and AURKA activate ERα by phosphorylating 
S118 and S167, respectively, and both phosphorylate S305 (Wang, Mazumdar et al. 2002, 
Rayala, Talukder et al. 2006, Zheng, Guo et al. 2014). Phosphorylation at these residues 
is correlated with endocrine resistance in hormone receptor-positive patients. ERα, in turn, 
upregulates expression of AURKA upon ligand binding (Jiang, Katayama et al. 2010). 
Here, we introduce an AURKA selective inhibitor alisertib, and a novel ATP-competitive 
small molecule inhibitor of group I PAKs, FRAX1036, and demonstrate the synergistic 
suppression of proliferation in human breast cancer cell lines (tamoxifen-sensitive and 
tamoxifen-resistant). The antitumor effect of combined inhibition was confirmed in 
xenograft models. Therefore, these results suggest that dual inhibition of AURKA and 
PAK1 is a promising therapeutic strategy in hormone receptor-positive breast cancer, 
especially in the settings of endocrine resistance.  
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MATERIAL AND METHODS 
 
Cell lines and cell culture 
The human breast cancer cell lines BT-474 (ATCC® HTB-20™) and T-47D (ATCC® 
HTB-133™) were obtained from ATCC (Manassas, VA). Both cell lines were cultured in 
RPMI-1640 medium supplemented with 10% fetal bovine serum, 1% GlutaMAX-I® 
(100×), and 100 μg/ml penicillin/ streptomycin antibiotic mix as previously described 
(Rusnak, Lackey et al. 2001, Yamashita, Iwase et al. 2003, Neve, Chin et al. 2006). 
Unique STR profile was confirmed for both cell lines. 
 
Reagents 
Aurora A kinase inhibitor alisertib (MLN8237) was purchased from MedChem Express 
(Monmount Junction, NJ). PAK group I inhibitor FRAX1036 was synthesized at the 
laboratory of Dr. William Wuest (Department of Chemistry, Temple University, 
Philadelphia, PA). RPMI 1640 medium, fetal bovine serum, penicillin/ streptomycin 
antibiotic mix were obtained from Cell Culture Facility, Fox Chase Cancer Center. 
GlutaMAX-I® (100×) was purchased from Life Technologies (Grand Island, NY). 
Tumor lysis buffer was prepared with T-PER™ Tissue Protein Extraction Reagent 
(Thermo Scientific, Rockford, IL) supplemented with PhosSTOP™ phosphatase inhibitor 
and cOmplete™ ULTRA protease inhibitor cocktails (Roche, Mannheim, Germany). 
Luminata™ Western HRP substrates (Classico and Crescendo) were purchased from 
EMD Millipore (Billerica, MA) and SuperSignal™ West HRP substrate kits (Pico and 
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Femto) were obtained from Thermo Scientific (Rockford, IL). Immun-Star™ AP 
substrate was purchased from Bio-Rad (Hercules, CA). 
 
The antibodies against phospho-AKT (Thr 308) and AKT (pan), phospho-ERα (Ser118), 
phospho-ERα (Ser167), PAK1, and histone H3 were purchased from Cell Signaling 
(Danvers, MA). Aurora A kinase antibody was from BD Transduction Laboratories (San 
Jose, CA). Antibody against Phospho-PAK 1, 2, 3(Ser141) was purchased from Life 
Technologies (Frederick, MD). Phospho-ERα (Ser305) antibody was obtained from EMD 
Millipore (Billerica, MA). All the primary antibodies were diluted to 1:1000 in 
Superblock T20 Blocking Buffer (Thermo Scientific, Rockford, IL) before incubation, 
unless stated otherwise in Table 1. HRP-conjugated secondary antibodies were obtained 
from GE Healthcare (Little Chalfont, UK), and diluted to 1:10000 in blocking Buffer 
before use. AP-conjugated secondary antibodies were purchased from Jackson 
ImmunoResearch (West Grove, PA), and diluted to 1:5000 in blocking buffer prior to use. 
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Table 1.    List of Antibody Information 
Antibody Company Catalog Number 
Biological 
Source 
Dilution Ratio 
Anti-mouse HRP 
conjugated antibody 
GE Healthcare UK 
Limited 
NA931-1ML Sheep 1:10000 
Anti-rabbit HRP 
conjugated antibody 
GE Healthcare UK 
Limited 
NA9340-1ML Donkey 1:10000 
Anti-mouse AP 
conjugated antibody 
Jackson 
ImmunoResearch 
115-055-003 Goat 1:5000 
Anti-rabbit AP 
conjugated antibody 
Jackson 
ImmunoResearch 
115-055-003 Goat 1:5000 
Vinculin Sigma-Aldrich V9131-.5ML Mouse 1:1000 
Aurora A (IAK1) 
BD Transduction 
Laboratories 
#610939 Mouse 1:1000 
phospho-PAK 
1,2,3(Ser141) 
Life Technologies #44-940G Rabbit 1:5000 
PAK 1 Cell Signaling #2602 Rabbit 1:5000 
phospho-AKT 
(Thr308) 
Cell Signaling #4056 Rabbit 1:1000 
AKT(pan) Cell Signaling #2920 Mouse 1:1000 
phospho-ERα 
(Ser167) 
Cell Signaling #5587 Rabbit 1:1000 
phospho-ERα 
(Ser305) 
EMD Millipore #07-962 Rabbit 1:1000 
ERα (D6R2W) Cell Signaling #13258 Rabbit 1:1000 
histone H3 (96C10) Cell Signaling #3638 Mouse 1:1000 
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Cell Viability Assay 
Viability of BT474 and T47D cells was evaluated by CellTiter-Glo assay (Promega, 
Madison, WI) after 4 different treatments: (1) FRAX1036, (2) alisertib, (3) combination 
of FRAX1036 and alisertib in 1:1.5 molar ratio, (4) vehicle (DMSO). Each drug was 
prepared in 8 serial dilutions with the dilution factor of 1.6. Cells were grown on opaque-
walled 96-well plates in antibiotic-free media for 24 hours before treatment was applied. 
After 96 hours of treatment, 100μl of CellTiter-Glo® Reagent was added each well, the 
plates were placed on a shaker for 2 minutes to achieve complete lysis of the cells and 
mixture of the reagents, and then incubated for an additional 8 minutes. The luminosity of 
each well was measured on GloMax™ 96 Microplate Luminometer. Luminosity of each 
well reflects the amount of ATP which is directly proportional to the number of live cells 
present in culture. Each drug concentration was tested in triplicates, and each experiment 
was performed in three or more biologic repetitions. IC50 for single agents and 
combination treatment was established for each cell line. Synergy was determined by 
Chou-Talaly method as previously described (Chou and Talalay 1984). 
 
Breast cancer mouse model and tissue collection 
Six-week-old non-obese diabetic /severe combined immunodeficient (NOD/SCID) 
female mice were obtained from the Animal Facility of Fox Chase Cancer Center. Prior 
to cell injection, estrogen pellets (~1mg 17β-estradiol/ pellet) were made and implanted 
to the mice as previously described (DeRose, Gligorich et al. 2013). Ten million T47D 
cells were suspended in Matrigel (BD Biosciences, San Jose, CA) (1:1, v/v), and then 
injected subcutaneously into mammary fat pads of the mice to establish orthotopic 
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xenografts. Body weight was monitored, and tumor length (L, the largest tumor diameter) 
and width (W, the perpendicular diameter) were measured with calipers three times per 
week. Tumor volume was calculated as 0.5 × (L × W2) mm3.  
 
When tumor volumes reached 150-160mm3, the mice were randomly assigned to four 
cohorts: 7.5 mg/kg (T47D) or 15 mg/kg (BT474) alisertib, 20 mg/kg FRAX1036, a 
combination of both, and Vehicle. Alisertib was dissolved in 10% 2-hydroxypropyl-β-
cyclodextrin with 1% sodium bicarbonate, FRAX1036 was formulated in 10% 2-
hydroxypropyl-β-cyclodextrin with 50mM citrate buffer (pH=3). Mice treated with 
vehicle were orally dosed with alisertib solvent in the morning, and FRAX1036 solvent 
in the afternoon. All the mice were treated for a total of 21 days of treatment, using 5 
days on/ 2 days off schedule.  
 
24 hours after the last treatment, mice were euthanized by CO2 asphyxiation, and tumors 
and organs were harvested. Three quarters of the tumors were snap-frozen in liquid 
nitrogen, and stored at -80 °C to be used for western blot analysis and in vitro kinase 
assay. The organs, as well as the remaining quarter of tumor, were fixed in 10% 
phosphate-buffered formaldehyde (formalin) and processed as paraffin embedded tissues. 
These tissues were prepared for pathological assessment as slides and stained with 
hematoxylin and eosin (H&E) and Ki-67 antibody by Pathology Facility in Fox Chase 
Cancer Center and stained with antibody against cleaved caspase-3 by University of 
Colorado School of Medicine. The slides were imaged and scored using Vectra 3.0 
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(PerkinElmer, Waltham, MA) and APERIO Image Analysis (Leica Biosystems Imaging, 
Buffalo Grove, IL)  
 
All experiments involving mice were approved by The Institutional Animal Care and Use 
Committee (IACUC) in Fox Chase Cancer Center. 
 
Preparation of Tumor Lysates 
Fresh frozen tumors were weighed and lysed in the tumor lysis buffer (1:5, w/v) at 4 °C. 
Then tumors were homogenized by PowerGen 125 Homogenizer (Fisher Scientific, 
Pittsburgh, PA), followed by ultrasonication using Model 550 Sonic Dismembrator 
(Fisher Scientific, Pittsburgh, PA). The lysates were centrifuged at 13000 rpm, 4 °C for 
30 minutes, and the supernatants were collected. Protein concentrations of whole lysates 
were measured using Pierce BCA assay kit as the manufacturer’s instructions (Thermo 
Scientific, Rockford, IL), and adjusted to 5 µg/µl.  
 
Western Blotting 
The lysates were mixed with 5× lane marker reducing sample buffer (Thermo Scientific, 
Rockford, IL), boiled for 5 minutes at 100 °C, and centrifuged at 13000 rpm, 1 minute. 
Then these samples were frozen in a mixture of solid CO2 and ethanol, and stored at -
80 °C until use. 50 µg of proteins were separated by size using BLOT 8% or 10% Bis-
Tris 15 well Mini Protein Gels (Life Technologies, Carlsbad, CA). Then the proteins 
were transferred to 0.45 µm Immobilon-P PVDF Transfer Membrane (EMD Millipore, 
Billerica MA) as the manufacturer’s instructions. Membranes were blocked in at room 
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temperature for 1 hour, and incubated with primary antibodies overnight at 4 °C on a 
rocker. Membranes were washed 3 times for 10 minutes each in PEST, followed by 1-
hour incubation with secondary HRP (1:10000) or AP (1:5000) antibodies at room 
temperature. The membranes were washed 3 times again. Then the membranes were 
incubated with HRP substrates or AP substrate for 5 minutes. Chemiluminescence was 
captured by X-ray films. The films were scanned by Epson Perfection V800 Photo 
Flatbed Scanner (Epson America Inc., Long Beach, CA). ImageJ Imaging and Processing 
Analysis Software (NIH, Bethesda, MD) was used for densitometric analysis, 
normalizing signal intensity of detected proteins to that of loading control (Vinculin). 
 
Immunoprecipitation and in vitro Kinase Assay 
Protein A/G Agarose beads (Pierce by Thermo Scientific, Rockford, IL) were mixed 
gently with cold PTY buffer (50 mM HEPES, 50 mM NaCl, 5 mM EDTA, 1% Triton X-
100, and 50 mM NaF). Then antibody against AURKA (BD Transduction Laboratories, 
San Jose, CA) were added to the mixture and incubated on the rotator at 4 °C for 4 hours. 
Mouse Immunoglobulin G (IgG) (Genetex, Irvine, CA) was used as negative control for 
immunoprecipitation.  
 
After antibody conjugation to the beads, beads were centrifuged at 7000 rpm, 4 °C for 3 
minutes, and supernatant was aspirated. The beads were then washed gently in cold PTY 
buffer, and centrifuged again. After 3 washes, immobilized bead conjugates were mixed 
with 500 µg tumor lysates in cold PTY buffer. For positive control, purified recombinant 
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AURKA was mixed with conjugates in PTY buffer. The mixtures were then incubated 
overnight on the rotator at 4 °C.  
 
After incubation mixtures were centrifuged, and supernatants were aspirated. The bead 
conjugates were mixed with 5 × kinase buffer containing purified AURKA substrate, 
histone H3 (Upstate, Charlottesville, VA), and [γ-32P] ATP mix that contains [γ-32P] 
ATP (BLU502A001MC, Perkin Elmer), Mg2+/ATP cocktail (20-113, EMD Millipore), 
and Milli-Q H2O (Cell Culture Facility, Fox Chase Cancer Center). Mixtures were then 
incubated at 32 °C for 30 minutes. Incubation was followed by addition of 2× lane 
marker reducing sample buffer (Thermo Scientific, Rockford, IL), and denaturation at 
100 °C for 5 minutes.  
 
After centrifuging at 13000 rpm for 1 minute supernatants were resolved by BOLT 12% 
Bis-Tris 17 well Mini Protein Gels (Novex by Life Technologies, Carlsbad, CA), and 
transferred to 0.45 µm Immobilon-P PVDF Transfer Membranes. The mini protein gels 
were stained with Simply Blue Safe Stain (LC6060, Thermo Scientific, Rockford, IL) 
after transfer. Membranes were then placed within a transparent plastic folder in an X-
Ray film cassette, and kept at -80°C in order to capture exposure on X-Ray films. After 
obtaining multiple exposures, membranes were incubated with primary antibody against 
histone H3 overnight and then processed as the aforementioned Western Blotting 
instructions. Signal intensity of phospho-histone H3 on 32P films was normalized to that 
of histone H3 on immunoblot films. 
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Statistical Analysis 
Statistical analysis was performed by Biostatistician Brian Egleston, or through Prism 5 
(GraphPad Software, San Diego, CA) by Yayi Feng, Elena Shagisultanova, and Vladislav 
Korobeynikov. 
 
RESULTS 
 
Inhibition of AURKA and PAK1 synergistically hampers cell survival of breast 
cancer cells in vitro and limits growth of mammary tumor xenografts in vivo. 
To investigate the effect of dual inhibition of AURKA and PAK1 on cell proliferation, 
CellTiter-Glo cell viability assays in tamoxifen-resistant and tamoxifen-sensitive human 
breast cancer cell lines BT474 and T47D  (Table 2) were conducted by my collaborator 
Dr. Elena Shagisultanova (Shagisultanova, Korobeynikov et al. 2016). Herein, we 
pharmacologically targeted AURKA and PAK1 by utilizing alisertib and FRAX1036 in 
both cell lines for 96 hours. Drug synergy was determined by Chou-Talaly method. 
Results demonstrated a dramatic synergistic effect of the alisertib and FRAX1036 
combination in reducing cell survival in both cell lines (Fig. 3A).  
 
Table 2.   Molecular Phenotypes of BT474 and T47D 
Cell lines PR ER HER2 
11q13 
amplification 
p53 PI3KCA Sensitivity to tamoxifen 
BT474 + + + amp mut mut tamoxifen-resistant 
T47D + + - non-amp mut mut tamoxifen-sensitive 
*amp - amplified, mut - mutated 
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To confirm the inhibitory effect on proliferation of these breast cancer cells in vivo. 
BT474 and T47D cells were injected into the mammary fat pads of 6-week-old 
NOD/SCID mice to establish orthotopic xenograft tumor models. Once implanted tumor 
volume reached 150 mm3, the mice were assigned into four cohorts and administered 
following treatments for 21 days: Vehicle, FRAX1036 20 mg/kg, alisertib 15 mg/kg 
(BT474) or 7.5 mg/kg BID (T47D), and a combination of FRAX1036 and alisertib. We 
observed more rapid growth of BT474 tumors in vehicle-treated group comparing to 
treatment cohorts: in the Vehicle group, the average tumor volume reached 930 mm3 by 
the end of treatment (Fig. 3B) (Shagisultanova, Korobeynikov et al. 2016). Mice dosed 
with either FRAX1036 or alisertib had smaller average tumor size (FRAX1036: 826 mm3, 
alisertib: 188 mm3), whereas combined FRAX-alisertib treatment significantly 
suppressed growth of BT474 tumors (55 mm3). T47D xenograft mice dosed with vehicle 
harbored smaller tumors (276 mm3) in the end of treatment compared to BT474 xenograft. 
Alisertib at 7.5 mg/kg and combination treatment completely eliminated tumor growth. 
FRAX1036 treatment alone showed a trend to retard the tumor progression at the 
beginning of the dosing. Therefore, the in vivo experiment demonstrates that FRAX1036 
or alisertib decreased tumor burden, and combination therapy further suppressed tumor 
growth in BT474 xenograft mouse model, which is statistically significantly better than 
either of the single agents. In T47D xenograft model, combination treatment overall 
resulted in a better inhibition of tumor growth compared to single agents. However, 
comparison of the effect of combination treatment to that of alisertib alone did not reach 
statistical significance.  
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Figure 3. Dual inhibition of AURKA and PAK1 by alisertib and FRAX1036 impairs 
survival of breast cancer cells in vitro and limits breast tumor growth in vivo. Cell 
viability assays were performed in BT474 andT47D cells after four different treatments: 
FRAX1036, alisertib, combination of FRAX1036 and alisertib in 3:2 molar ratio, and 
vehicle (DMSO). Synergy was analyzed by the Chou-Talalay method. In in vivo study, 
BT474 and T47D cells were injected to mammary fat pads of NOD/SCID mice. When 
the tumor volume reached 150 mm3, mice were administered with vehicle, FRAX1036 
or/and alisertib as described in “Materials and Methods”. The tumor growth was 
monitored three times per week. A. Combined use of alisertib and FRAX1036 exerted 
synergistic effect on cell death in T47D and BT474 breast cancer cell lines. IC50 of each 
treatment is indicated in the graphs. Chou Talalay analysis of synergy indicated that 
alisertib and FRAX1036 were synergistic (CI<1) or had at least additive effect (CI=1) in 
the tested concentration range (CI – combination index; synergy: CI<1; additive effect: 
CI=1; antagonistic effect: CI>1). B. Alisertib impeded tumor growth, and combination of 
alisertib and FRAX1036 led to a decline of tumor burden in BT474 and T47D breast 
cancer xenograft models. **P<0.01. 
  
27 
 
Combination of alisertib and FRAX1036 suppresses proliferation and promotes 
apoptosis in vivo 
In order to determine the changes in cell proliferation and apoptosis caused by alisertib 
and FRAX1036, tumors were harvested at the end of treatment, and histopathological 
assessment performed. Immunohistochemical (IHC) staining was performed using 
antibodies against Ki-67 to indicate proliferation and cleaved caspase-3 to indicate 
apoptosis. As expected, FRAX and alisertib cooperatively led to a significant decline in 
proliferative cell population, and induced caspase-3 cleavage in BT474 orthotopic tumors 
(Fig. 4B-E) (Shagisultanova, Korobeynikov et al. 2016). Assessment of hematoxylin and 
eosin (H&E) stained slides demonstrated many few cancer cells and larger fibrotic and 
necrotic areas in tumors of the combination-treated cohort as compared with those in 
other treatment groups (Fig. 4A). Alisertib alone at the dose of 15mg/kg also decreased 
proliferation and promoted apoptosis in tumors collected from BT474 xenograft. H&E 
staining revealed that alisertib as well as FRAX1036 led to an increase in fibrotic area in 
BT474 tumor samples, albeit to a lesser degree compared to combination treatment. IHC 
analysis in tumors after 21 days of FRAX1036 treatment did not show significant 
changes in Ki-67 and cleaved caspase-3. This is in accordance with the fact that FRAX 
initially suppressed growth of BT474 xenografts, however, at the end of the experiment 
this effect was lost. These data suggest that alisertib alone was used at a concentration 
sufficient to inhibit proliferation and induce cell death in this model, while concurrent use 
of alisertib and FRAX1036 diminished proliferation and enhanced apoptosis in BT474 
xenograft.  
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Previously we observed T47D tumors shrank during the combination therapy (Fig. 3B). 
However, there was no discernible difference in Ki-67 positive cell populations between 
all the treatment groups of T47D xenograft (Fig. 4B, D). Interestingly, tumors with 
alisertib treatment alone had a decrease in cleaved caspace-3 staining compared to those 
with FRAX1036 treatment (Fig. 4C, E). 
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Figure 4. Combination of alisertib and FRAX1036 suppresses proliferation and 
promotes apoptosis in vivo. Orthotopic tumors were collected after the 21-day treatment, 
and processed as paraffin embedded tissues, which was followed by H&E staining (A), 
IHC staining using anti-Ki-67 (B) and anti-cleaved caspase 3 antibodies (C). 
Quantification of Ki-67 and cleaved caspase 3 stained cells were performed using 
APERIO e-pathology (D, E).  A. In BT474, FRAX1036 or alisertib treatment led to an 
increase in fibrotic area, and combination treatment effectively decreased tumor cell 
population resulting in large areas of fibrosis. In T47D, FRAX1036 alone did not result in 
the increase of fibrotic area, while both Alisertib and combination treatment resulted in 
the increased fibrosis. B, D. Alisertib and combination treatment suppressed proliferation 
in BT474 orthotopic tumors as shown by decrease in Ki-67, which was statistically 
significantly different between vehicle and combination treatment, FRAX1036 and 
alisertib, and FRAX1036 and combination treatment. This effect was lost after 21-day 
treatment in T47D xenograft mice. C, E. Apoptosis was induced in BT474 tumors upon 
combination treatment, which was statistically significantly different from those with 
vehicle treatment. No difference between vehicle and treatment groups were found in 
T47D tumors, although and FRAX1036 exerted stronger pro-apoptotic effect in T47D 
tumors compared to alisertib. **P<0.01. 
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Combined treatment with alisertib and FRAX1036 reduces estrogen receptor α 
(ERα) phosphorylation and signaling activity in HR-positive breast cancer. 
To further explore the short-term effect of alisertib and FRAX1036 in HR-positive breast 
cancer, we established BT474 and T47D xenograft models for a three-day treatment in 
order to confirm results of in vitro cell viability experiments based on 96 hours of drug 
exposure (Fig. 3A). Using Western blotting to detect protein levels in tumor lysates, we 
found that FRAX1036 as a single agent effectively reduced levels of phosphorylated 
PAK1 in both BT474 and T47D orthotopic tumors (Fig. 5A). Alisertib enhanced the 
FRAX1036 inhibitory effect, resulting in a depletion of phosphorylated PAK1 in BT474 
tumors. T47D xenograft tumors treated with FRAX1036 alone or in combination with 
alisertib also had suppressed phosphorylation of PAK1. However, in contrast to BT474, 
T47D tumors had increased expression of total PAK1 after treatment with our targeted 
agents, which could have been a compensatory mechanism diminishing antitumor 
activity of FRAX1036 alone or in combination with alisertib in T47D tumor xenograft 
model.  
 
 We validated inhibition of AURKA by alisertib using an in vitro kinase assay. BT474 
and T47D tumor lysates were subjected to immunoprecipitation by protein A/G agarose 
beads conjugated with anti-AURKA antibody.  Histone H3 was used as AURKA 
substrate to incubate with the immunoprecipitates and 32P-labeled ATP, as it is an 
established substrate phosphorylated by AURKA in vitro (Crosio, Fimia et al. 2002). The 
in vitro kinase assay and coupled Western Blot analysis demonstrated that alisertib 
treatment suppressed AURKA activity in both xenograft models, and reduced up to 70% 
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of phospho-histone H3 in the presence of FRAX1036 in BT474, but not T47D orthotopic 
tumors (Fig. 5B). 
 
Previous published studies revealed that both PAK1 and AURKA interact with ERα and 
modulate ERα transactivation activity through phosphorylation at serine residues, S118 
and S167 in the AF-1 domain, respectively, and S305 at the hinge domain (Rayala, 
Talukder et al. 2006, Zheng, Guo et al. 2014). The phosphorylation of these residues is 
involved in ligand-independent activation of ERα signaling. Therefore, we wanted to 
determine if inhibition of PAK1 and AURKA by FRAX1036 and alisertib represses ERα 
phosphorylation and signal transduction. Western Blot analysis showed that FRAX1036 
decreased phosphorylated ERα-S167 and ERα-S305 levels in both BT474 and T47D 
xenograft models, whereas alisertib caused similar effect but to a lesser extent, only in 
BT474 tumors (Fig. 6A, B). Combined use of FRAX1036 and alisertib also inhibited 
phosphorylation of ERα at these serine residues in BT474 orthotopic tumors. However, 
the combination therapy surprisingly tended to reverse the effect in T47D xenograft. 
 
Cytoplasmic and membrane ERα exerts non-genomic effect in breast cancer cells upon 
ligand binding. When ERα activation occurs, it recruits various molecules to the cell 
membrane such as membrane receptors (receptor tyrosine kinases and G-protein coupled 
receptors), adaptor proteins (Src, Shc, etc.), as well as protein kinases including PI3K, 
and AKT. Activated ERα induces rapid phosphorylation of adapter proteins and thus 
transduces signals through various pathways including PI3K/AKT (Arpino, Wiechmann 
et al. 2008). Activated AKT increases ERα transcriptional activity through 
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phosphorylation at S167 (Campbell, Bhat-Nakshatri et al. 2001). Interestingly, PAK1 is 
promotes AKT activation to enhance growth signal autonomy in cancer cells (Higuchi, 
Onishi et al. 2008), while AKT, in turn, phosphorylates PAK1 and enhances PAK1 
activity, even though the PAK1 activation by AKT is weaker than activation by Cdc42 or 
Rac (Zhou, Zhuo et al. 2003). Therefore, we used antibodies against phosphorylated and 
total AKT proteins to examine activation status of PI3K/AKT signaling pathway, aiming 
to investigate the mechanisms underlying distinctive consequences of treatments in 
BT474 and T47D xenograft models. We found that BT474 xenograft mice treated with 
FRAX1036 or/and alisertib had a substantial decline of phosphorylated and total AKT 
levels in solid tumors. Notably, combination treatment completely depleted 
phosphorylation of AKT and caused a 90% reduction of total AKT proteins (Fig. 6C). In 
T47D solid tumors, FRAX1036 treatment also decreased both levels of activated and 
total AKT. However, alisertib and combination group had a lower level of 
phosphorylated AKT, and both treatments exerted a reverse effect in total AKT protein 
expression as compared to control group, possibly representing a compensatory 
mechanism.  
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Figure 5. Concurrent use of alisertib and FRAX1036 decreases phosphorylation of 
PAK1 and AURKA kinase activity in tamoxifen-resistant breast cancer. Xenograft 
mice were dosed for 3 days before euthanasia and tumor collection. Tumors were lysed 
and homogenized, and the tumor lysates were subjected to Western blotting analysis and 
in vitro kinase assay. A. Alisertib enhanced FRAX1036 inhibitory effect on PAK1 
phosphorylation in BT474 xenograft model. B. Combined treatment of FRAX1036 and 
alisertib cooperatively suppressed AURKA kinase activity in BT474, but not in T47D 
tumors. *P<0.05, ****P<0.0001 relative to vehicle treated.  
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Figure 6. Combined treatment with alisertib and FRAX1036 reduces ERα 
phosphorylation and signaling activity in tamoxifen-resistant breast cancer. A-B. 
Combination of FRAX1036 and alisertib exerted reverse effect on ERα phosphorylation 
in BT474 and T47D xenograft models. BT474 orthotopic tumors had decreased level of 
p-ERα(S167) (A) and p-ERα(S305) (B), whereas T47D tumors had an increase in ERα 
phosphorylation. C. Phosphorylation of AKT was downregulated upon dual inhibition of 
PAK1 and AURKA. *P<0.05, ****P<0.0001 relative to vehicle treated. 
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DISCUSSION 
 
Several studies have emphasized the significant roles of AURKA and PAK1 in tumor 
development and progression of breast cancer. However, co-targeting AURKA and 
PAK1 in breast cancer, especially in the context of tamoxifen resistance, has not 
previously been examined. In this study, we demonstrated that AURKA and PAK1 
inhibitors cooperatively suppressed cell viability in tamoxifen-resistant and tamoxifen-
sensitive breast cancer cell lines in vitro (Fig. 3A). We also observed an antitumor effect 
of alisertib and FRAX1036 in both xenograft models.  
 
When alisertib and FRAX1036 were used as single agents, breast cancer cells generally 
were more sensitive to FRAX1036 in vitro (Fig. 3A). In contrast, alisertib decreased 
tumor volume to a greater degree than FRAX1036 in both xenograft models (Fig. 3B), 
suggesting that inhibition of tumor growth by alisertib is predominant in vivo. The 
diverse responses might result from differences in various aspects such as duration of the 
treatments (3 days for in vitro study versus 21 days for in vivo study), tumor 
microenvironment, efficacy of drug delivery, and the biostability of these drugs in 
different experimental systems. The results of tumor volume measurement (Fig. 3B) and 
Ki-67 staining (Fig. 4B, D) reveal that alisertib effectively limited the growth of breast 
tumors. However, alisertib reduced proliferation in BT474 to a greater extent compared 
to T47D orthotopic tumors, which might result from the higher dosing concentration of 
alisertib for BT474 xenograft mice (15mg/kg BID for BT474 cohorts versus 7.5mg/kg 
BID for T47D cohorts).  
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BT474 xenograft mice had a greater response to FRAX1036 alone compared to T47D 
cohorts. FRAX1036 enhanced the antitumor effect of alisertib in the BT474 cohorts with 
combination treatment, whereas there was no significant difference in tumor volume 
between T47D xenograft mice with alisertib alone and combination treatments (Fig. 3B). 
These results indicate that FRAX1036 as a single agent or in combination with alisertib 
might be more beneficial to tamoxifen-resistant tumors, as represented by BT474 cancer 
cell line. One of the potential explanations is that T47D tumors had a lower growth rate 
compared to BT474 tumors, which led to a small effect size shown in tumor volume 
measurement. BT474 tumors generally grow faster than T47D, partially due to HER2 
amplification/ overexpression, a major difference between two cell lines in molecular 
phenotypes (Table 2). HER2 is overexpressed in BT474 cells, while T47D cells are 
identified as HER2 negative (Neve, Chin et al. 2006). HER2 overexpression has been 
correlated with more aggressive phenotype in breast cancer. HER2 hyperactivation 
caused by amplification or overexpression provides an additional stimulus for 
proliferation of HR-positive cancer cells. It has been previously shown that protein level 
and function of PAK1 are associated with HER2 overexpression in ER-positive breast 
cancer, but not in ER-negative breast cancer. Suppression of PAK1 activity hampers 
HER2-driven tumorigenicity in vivo, which implicates that PAK1 is an important 
mediator in HER2 signaling in tumor development (Arias-Romero, Villamar-Cruz et al. 
2010). Better response to FRAX1036 in BT474 xenograft mice might be also due to the 
fact that chromosomal region 11q13 is amplified in BT474, but not T47D breast cancer 
cells. As previously discussed, PAK1 gene is clustered with other oncogenes within the 
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chromosomal region 11q13, and 11q13 amplification is one of the mechanisms 
explaining PAK1 dysfunction in ovarian and breast malignancy (Lundgren, Holm et al. 
2008). The Chernoff group has demonstrated that ovarian cancer cells with 11q13 
amplification have higher sensitivity to FRAX1036 compared to cells without PAK1 
overexpression (Prudnikova and Chernoff 2016). Therefore, it is possible that BT474 
xenograft mice had a greater response to FRAX1036 as a single agent or in combination 
with alisertib than T47D cohorts due to the presence of 11q13 amplicon and HER2 
amplification/overexpression.  
 
We confirmed the inhibitory efficacy of FRAX1036 in vitro by detecting the levels of 
phosphorylated and total PAK1 (Fig. 5A). The results of Western Blot analysis suggest 
that FRAX1036 significantly suppresses PAK1 activation in both xenograft models, 
showing its potency against PAK1 (Chow, Dong et al. 2015). Interestingly, alisertib also 
inhibited PAK1 phosphorylation, which might be due to the fact that alisertib indirectly 
suppresses PI3K/AKT/mTOR pathway and decreases the level of phosphorylated AKT 
(Fig. 6C) that normally phosphorylates and promotes PAK1 activity (Wang, Li et al. 
2015). We found a decrease in the protein level of total PAK1 in BT474 cohorts dosed 
with FRAX1036 alone or combination. A similar effect has been reported in a Kras-
driven skin cancer model treated with another group I-specific PAK inhibitor, FRAX597 
(Chow, Jubb et al. 2012). Downregulation of total PAK1 level by FRAX597 is disrupted 
when cells are treated with proteasome inhibitor MG132, which indicates that FRAX597 
might serve as a destabilizing agent, in addition to its function as an ATP-competitive 
inhibitor (Radu, Semenova et al. 2014). Since FRAX1036 is optimized on the basis of 
39 
 
arylamino pyridopyrimidinone PAK inhibitors including FRAX597, FRAX1036 might 
also have a dual inhibitory effect on PAK1 (Ong, Gierke et al. 2015). However, such 
inhibition was not seen in the T47D xenograft model, suggesting that the additional effect 
might be cell-specific, or other compensatory mechanisms might render T47D cells 
overcome depletion of total PAK1 protein by FRAX1036.     
 
In intro kinase assays demonstrated that alisertib is able to target AURKA and 
downregulate its kinase activity of AUKRA to phosphorylate histone H3 (Fig. 5B). 
FRAX1036 also led to a decrease in histone H3 phosphorylation when used as a single 
agent or in combination with alisertib, in support of previous studies that PAK1 can 
induce AURKA activation by directly phosphorylating AURKA as well as its activators 
(Edwards, Sanders et al. 1999, Vadlamudi, Li et al. 2004, Zhao, Lim et al. 2005). 
FRAX1036 and alisertib cooperatively suppressed AURKA kinase activity in BT474 
tumors, however, did not exert a synergistic effect in T47D cohort. Notably, one 
specimen in this cohort displayed a high level of phosphorylated histone H3, whereas the 
remaining samples exhibited low level of AURKA kinase activity, implicating that 
heterogeneity existed in this cohort and it might disrupt the consistency of the results. It 
would be important to analyze additional animals in the future.  
 
We assessed ERα phosphorylation at S167 and S305 in both xenograft models (Fig. 6A, 
B). In BT474 xenograft tumors, p-ERα(S167) level in the tumors treated with alisertib is 
similar to that with FRAX1036 or combination treatment. Since PAK1 does not directly 
phosphorylate ERα at S167, reduced level of p-ERα(S167) caused by FRAX1036 may 
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mainly arise from the decreased AURKA kinase activity upon PAK1 inhibition (Fig. 5B). 
A reduced level of p-ERα(S305) following alisertib treatment is consistent with the 
results from the Cheng group, showing that AURKA promotes phosphorylation of ERα at 
S305 (Zheng, Guo et al. 2014). FRAX1036 or combination treatment caused a larger 
reduction than alisertib, which is compatible with our hypothesis that FRAX1036 reduces 
ERα phosphorylation at S305 by inhibiting PAK1 activity to phosphorylate this residue 
directly, and also indirectly (by impairing AURKA kinase activity).  
 
Similar to the results in BT474 xenograft mice, FRAX1036 downregulated ERα 
phosphorylation at both S167 and S305 in T47D tumors. However, alisertib didn’t 
suppress ERα phosphorylation on these residues, and combination treatment even 
elevated the levels of p-ERα(S167) and p-ERα(S305). These significant differences 
between BT474 and T47D tumor cell lines may potentially result from the fact that 
BT474 is a tamoxifen-resistant cell line, while T47D is sensitive to tamoxifen. In BT474 
cells, pathway of ligand-independent activation of ER may be very active, while ligand-
dependent activation of ER may be less critical for cell survival. In this circumstance, 
inhibition of PAK1 and AURKA may result in significant suppression of ligand-
independent phosphorylation of ERα. T47D cells are not tamoxifen-resistant and possibly 
rely much more on ligand-dependent ERα signaling with only some contribution of 
ligand-independent activation of ER. When ligand-independent signaling is suppressed, 
cells continue using the main pathway of ligand-dependent ER activation, and significant 
amount of phosphorylated ERα may be present as a result of normal signaling through 
E2. All mice in the xenograft experiment were supplemented with estrogen pellets and 
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therefore had a substantial level of estradiol in the blood, making this hypothesis feasible. 
Another possible explanation is that alisertib might upregulate expression of ERα in some 
cell lines, and some protein kinases that can also phosphorylate S167 and S305 residues 
of ERα. To further investigate the suppression of cancer cell growth by FRAX1036 and 
alisertib, we might generate BT474 and T47D cells that express ERα with 
phosphomimetic mutation at S167 or S305, or utilize CRISPR to deplete ERα in both cell 
lines, and perform cell viability assay to explore the influence of combination treatment 
when ERα is constitutively active or absent in breast cancer cells. 
 
AKT activity supports cell survival and prevents apoptosis. AKT activation can be 
modulated by PAK1, AURKA, and ERα. PAK1 serves as a scaffold protein to facilitate 
interaction between PDK1 and AKT and thus promotes activation of PI3K/AKT pathway 
(Higuchi, Onishi et al. 2008). AKT can phosphorylate PAK1 and thus enhances its 
activity in cell migration (Zhou, Zhuo et al. 2003). AURKA promotes phosphorylation of 
AKT, which activates MDM2-mediated degradation of p53 and prevents cell cycle arrest 
and apoptosis (Yang, He et al. 2006). ERα promotes PI3K/AKT activation through non-
genomic signaling, and AKT, in turn, upregulates ERα activity by phosphorylating S167 
(Campbell, Bhat-Nakshatri et al. 2001, Arpino, Wiechmann et al. 2008). Western Blot 
analysis demonstrated a striking effect of FRAX1036 or/and alisertib on inhibition of 
both AKT protein level and activation in BT474 xenograft models (Fig. 6C). However, 
such inhibition only moderately influenced the level of phosphorylated AKT in T47D 
orthotopic tumors. Results of cleaved caspase-3 staining in both xenograft tumors (Fig. 
4C, E) indicate that the level of apoptosis is correlated with suppression of AKT activity, 
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which also reflects that BT474 is more sensitive to AKT inhibition indirectly by alisertib 
and FRAX1036. This might be explained by different molecular phenotypes between two 
cell lines (Table 2). Breast cancer cells with HER2 amplification or PIK3CA mutation 
(PI3K-encoding gene) are more dependent on AKT signaling (She, Chandarlapaty et al. 
2008). Oncogenic mutation of PIK3CA is present in both BT474 and T47D cell lines 
(Hollestelle, Elstrodt et al. 2007), and BT474 is HER2-positive. Therefore, HER2 
amplification and PIK3CA mutation in BT474 cell lines might synergistically result in 
higher sensitivity to AKT suppression by FRAX1036 and alisertib.  
  
Phosphorylation at S167 and S305 residues is associated with elevated ERα 
transactivation activity. Therefore, further investigation should focus on the influence of 
AURKA and PAK1 inhibition on transcription of ER-targeted genes, such as VEGF and 
PS2. CCND1 might be another ER-regulated gene that we should take into consideration. 
CCND1 is an oncogene that encodes cyclin D1, a key regulator of G1 progression in cell 
cycle. Activation of PAK1, AURKA, and ERα can enhance expression of CCND1. Thus, 
CCND1 might be downregulated upon treatment of alisertib or/and FRAX1036, which 
contributes to suppression of proliferation in HR-positive breast cancer.  
 
Further, signaling molecules in MAPK pathway might be involved in the PAK1-
AURKA-ERα network by activating ERα, and perhaps conferring tamoxifen resistance. 
PAK1 can activate ERK by phosphorylation of c-RAF at S338 and MEK1 at S298, or by 
its function as a scaffold protein to promote interaction between RAF and ERK (Radu, 
Semenova et al. 2014). Non-genomic effect of ERα triggers activation of 
43 
 
RAF/MEK/MAPK pathway, and MAPK, in turn, modulates ERα activity by ligand-
independent phosphorylation at S104, S106 and S118 (Kato, Endoh et al. 1995, Thomas, 
Sarwar et al. 2008). AURKA enhances MEK/ERK pathway in colorectal cancer, and 
AURKA expression is induced upon MAPK activation in pancreatic cancer, suggesting a 
possible positive feedback loop between AURKA and MAPK (Katsha, Belkhiri et al. 
2015). Interestingly, breast cancer cells with HER2 overexpression become more 
dependent on ERK pathway upon PI3K/AKT/mTOR suppression, and compensatory 
activation of ERK pathway leads to enhanced HER2 activation. AKT inhibitors in 
combination with anti-HER2 monoclonal antibody trastuzumab or MEK1/2 inhibitors 
eradicate the compensatory activation of MAPK pathway (Serra, Scaltriti et al. 2011). 
Since PAK1, AURKA, and ERα regulate activation of both PI3K/AKT and MAPK 
pathways, the balance between both pathways in HR-positive breast cancer would 
influence the antitumor effect of alisertib and FRAX1036. Future experiments should 
explore the long term effect of combination treatment. Our study has shown that 
combination of FRAX1036 and alisertib may be the most beneficial in HR-positive / 
HER2-positive breast cancer. The next logical step is to combine alisertib and 
FRAX1036 with HER2 targeted agents (herceptin and pertuzumab) to prevent drug 
resistance and tumor progression due to upregulation of HER2 signaling.
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